

Neoplasms Solid Tumors

**An Extension Study in Participants Previously Enrolled in
a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored
Atezolizumab Study (IMbrella C)**

Trial Status
Recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT05112965 YO42713

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and do not have access to the study treatment locally, continue to receive study treatment in this extension study.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT05112965 YO42713
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No